Medical Factors Affecting Patency of Arteriovenous Access

Seminars in Vascular Surgery

Volumn 17, Issue 1, 2004, Pages 25-31

  Abularrage, Christopher J ^a   Sidawy, Anton N ^a   Weiswasser, Jonathan M ^a   White, Paul W ^a   Arora, Subodh ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ARTERIOVENOUS FISTULA; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CLINICAL TRIAL; COMPRESSION; ENDOTHELIUM CELL; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; HYPERCOAGULABILITY; HYPOALBUMINEMIA; HYPOTENSION; MORBIDITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SURGICAL PATIENT; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ACCESS; VASCULAR ENDOTHELIUM; VASCULAR PATENCY;

EID: 1542426359     PISSN: 08957967     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semvascsurg.2003.11.006     Document Type: Article

References (78)

1. US Renal Data System: USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
2. Feldman H, Kobrin S, Wasserstein A: Complications of vascular access are associated with 20% of all hospitalizations. Hemodialysis access morbidity. J Am Soc Nephrol 7:523-535, 1996
3. Roselaar S, Nazhat N, Winyard P, et al: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
4. Descamps-Latscha B, Goldfarb B, Nguyen A: establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemolyzed patients: A randomized prospective study. Nephron 59:279-285, 1991
5. Toborek M, Wasik T, Drodz M, et al: Effects of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 41:1229-1232, 1992
6. Himmelfarb J, Ault K, Holbrook D, et al: Intradialytic granulocyte reactive oxygen species production: A prospective crossover trial. J Am Soc Nephrol 4:178-186, 1993
7. Weiss M, Scivittaro V, Anderson J: Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 37:970-980, 2001
8. Masood I, Porter K, London N: Endothelin-1 is a mediator of intimal hyperplasia in organ culture of human saphenous vein. Br J Surg 84:499-503, 1997
9. Wilkie M, Khandan-Nia N, Ghatei A, et al: Does the arteriovenous fistula in chronic hemodialysis patients stimulate endothelin-1 release? Nephrol Dial Transplant 7:1019-1021, 1992
10. Chuang YC, Chen JB, Yang LC, et al: Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transplant 18:947-954, 2003
11. Domoto D, Bauman J, Joist J: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 62:737-743, 1991
12. Swedberg S, Brown B, Sigley R, et al: Intimal fibromuscular hyperplasia at the venous anastamosis of PTFE grafts in hemodialysis patients. Circulation 80:1726-1736, 1989
13. Mattana J, Effiong C, Kapasi A, et al: Leukocyte-polytetrafluorethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-α secretion. Kidney Int 52:1478-1485, 1997
14. Ejerblad S, Ericsson J, Eriksson I: Arterial lesions of the radial artery in uremic patients. Acta Chir Scand 145:415-428, 1979
15. Kim Y, Song H, Yoon S, et al: Preexisting intimal hyperplasia of radial artery is associated with early failure of radiocephalic arteriovenous fistula in hemodialysis patients. Am J Kidney Dis 41:422-428, 2003
16. Olsson LF, Odselius R, Ribbe E, et al: Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas. Am J Kidney Dis 38:377-383, 2001
17. Conlon P: Vascular access for hemodialysis, in Owen W, Periera B, Sayegh M (eds): Dialysis and Transplantation. Philadelphia, PA, W. B. Saunders Company, 2000, p 86
18. Barth C, Boer W, Garzoni D, et al: Characteristics of hypotension-prone haemodialysis patients: Is there a critical relative blood volume? Nephrol Dial Transplant 18:1353-1360, 2003
19. Windus W: The effect of comorbid conditions on hemodialysis access patency. Adv Ren Replace Ther 1:148-154, 1994
20. Miller P, Carlton D, Deierhoi M, et al: Natural history of arteriovenous graft in hemodialysis patients. Am J Kidney Dis 36:68-74, 2000
21. McCully K: Vascular pathology of homocysteinemia: Implications for the pathogenesis of atherosclerosis. Am J Pathol 56:111-128, 1969
22. Taylor L Jr, Moneta G, Sexton G, et al: Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29:8-19, 1999
23. den Heijer M, Koster T, Blom H, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762, 1996
24. Finkelstein JD: Regulation of homocysteine metabolism, in Carmel R, Jacobsen DW (eds): Homocysteine in health and disease. New York, NY, Cambridge University Press, 2001, pp 92-99
25. Cook J, Taylor L, Orloff S, et al: Homocysteine and arterial disease, experimental mechanisms. Vascul Pharmacol 38:293-300, 2002
26. McCully K: Homocysteine and vascular disease. Nat Med 2:386-389, 1996
27. Rajkumar V, Ragatzki P, Sima A, et al: Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: Implications for therapy. Endocr J UK 11:57-60, 1999
28. Fukasawa M, Matsushita K, Kamiyama M, et al: The methylenetetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 41:637-642, 2003
29. Manns B, Burgess E, Parsons H, et al: Hyperhomocysteinemia, anticardiolipin status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 55:315-320, 1999
30. Hojs R, Gorejak M, Ekart R, et al: Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 24:215-222. 2002
31. Sirrs S, Duncan L, Djurdjev O, et al: Homocysteine and vascular access complications in hemodialysis patients: Insights into a complex metabolic relationship. Nephrol Dial Transplant 14:738-743, 1999
32. Shemin D, Lapane K, Bausserman L, et al: Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 10:1095-1099, 1999
33. Carmody B, Arora S, Avena R, et al: Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. J Vasc Surg 30:1121-1128. 1999
34. Spence J, Cordy P, Kortas C, et al: Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily. Am J Nephrol 19:405-410, 1999
35. Hong S, Yang D, Chang S: Plasma homocysteine, vitamin b6, vitamin b12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. Am J Nephrol 18:367-372, 1998
36. Wilcken D, Dudman N, Tyrrell P, et al: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37:697-701, 1998
37. Thambyrajah J, Landray M, McGlynn F, et al: Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 102:871-875, 2000
38. Bostom A, Shemin D, Lapane K, et al: High dose vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
39. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al: Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study. J Am Soc Nephrol 11:1106-1116, 2000
40. Dierkes J, Domrose U, Ambrosch A, et al: Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 51:108-115, 1999
41. Bostom A, Shemin D, Bagley P, et al: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000 101:2829-2832. 2000
42. Yango A, Shemin D, Hsu N, et al: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 59:324-327. 2001
43. Hauser A, Hagen W, Rehak P, et al: Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. Am J Kidney Dis 37:758-765, 2001
44. Garcia-Martin F, DeArriba G, Carrascosa T, et al: Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 6:543-547, 1991
45. Grönhagen-Riska C, Teppo A, Helantera A, et al: Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. BMJ 300:1696-1697, 1990
46. Haviv Y: Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: Cause or effect? Nephron 86:447-454, 2000
47. Brunet P, Aillaud M, San Marco M, et al: Antiphospholipids in hemodialysis patients: Relationship between lupus anticoagulant and thrombosis. Kidney Int 48:794-800, 1995
48. Prakash R, Miller C, Suki W: Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 26:347-352, 1995
49. Schaeffer E, Lamon-Fava S, Jenner J, et al: Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999-1003, 1994
50. Cressman M, Heyka R, Paganini E, et al: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
51. Goldwasser P, Avram M, Collier J, et al: Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 24:785-794, 1994
52. Astor B, Eustace J, Klag M, et al: Race-specific association of lipoprotein(a) with vascular access interventions in hemodialysis patients: The CHOICE study. Kidney Int 61:1115-1123, 2002
53. Fodinger M, Mannhalter C, Pabinger I, et al: Resistance to activated protein C (APC): Mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant 11:668-672, 1996
54. Sampram E, Lindblad B: The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions. Eur J Vasc Endovasc Surg 22:134-138, 2001
55. Murphy R, Donoghue C, Nallen R, et al: Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 20:266-270, 2000
56. Irish A, Green F, Gray D, et al: The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 64:604-607, 1997
57. LeSar C, Merrick H, Smith M: Thrombotic complications resulting from hypercoaguable states in chronic hemodialysis. J Am Coll Surg 189:73-81, 1999
58. Diskin C, Stokes T, Pennell A: Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 64:1-26, 1993
59. Rayner H, Pisoni R, Gillespie B, et al: Creation, cannulation and survival of arteriovenous fistulae: Data from the dialysis outcomes and practice patterns study. Kidney Int 63:323-330, 2003
60. Avom J, Winkelmayer W, Bohn R, et al: Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 55:711-716, 2002
61. Goransson L, Bergrem H: Consequences of late referral of patients with end-stage renal disease. J Intern Med 250:154-159, 2001
62. Chesser AM, Baker LR: Temporary vascular access for first dialysis is common, undesirable and usually avoidable. Clin Nephrol 51:228-232, 1999
63. Kudva A, Hye R: Management of infectious and cutaneous complications in vascular access. Semin Vasc Surg 10:184-190, 1997
64. Saeed Abdulrahman I, Al-Mueilo S, Bokhary H, et al: A prospective study of hemodialysis access-related bacterial infections. J Infect Chemother 8:242-246, 2002
65. Lentino J, Baddour L, Wray M, et al: Staphylococcus aureus and other bacteremias in hemodialysis patients: Antibiotic therapy and surgical removal of access site. Infection 28:355-360, 2000
66. Brock J, Sussman M, Wamsley M, et al: The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. J Vasc Surg 16:904-910, 1992
67. Wetzig G, Gough I, Fumival C: One hundred cases of arteriovenous fistula for haemodialysis access: The effect of cigarette smoking on patency. Aust N Z J Surg 55:551-554, 1985
68. Ravani P, Marcelli D, Malberti F: Vascular access surgery managed by renal physicians: The choice of native arteriovenous fistulas for hemodialysis. Am J Kidney Dis 40:1264-1276, 2002
69. Puskar D, Pasini J, Savic I, et al: Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J 43:306-311, 2002
70. Hodges T, Fillinger M, Zwolak R, et al: Longitudinal comparison of dialysis access methods: Risk factors for failure. J Vasc Surg 26:1009-1019, 1997
71. Leaf D, Macrae H, Grant E, et al: Isometric exercise increases the size of forearm veins in patients with chronic renal failure. Am J Med Sci 325:115-119, 2003
72. Saran R, Dykstra D, Wolfe R, et al: Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40:1255-1263, 2002
73. Sreedhara R, Himmelfarb J, Lazarus J, et al: Antiplatelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45:1477-1483, 1994
74. Taber T, Maikranz P, Haag B, et al: Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia. ASAIO J 41:842-846, 1995
75. Huang P, Hawthorne W, Peng A, et al: Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. Am J Surg 181:492-498, 2001
76. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300:573-578, 1990
77. DeMarchi S, Cecchin E, Falleti E, et al: Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8:1147-1156, 1997
78. Churchill D, Muirhead N, Goldstein M, et al: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4:1809-1813, 1994